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Introduction
It is with enormous excitement, last month, that the
prostate cancer–mapping community acknowledges the
cloning and characterization, by Tavtigian et al. (2000),
of a hereditary prostate cancer (HPC) susceptibility gene,
HPC2/ELAC2. In the past 5 years, investigators in the
field have struggled, with mixed success, to localize genes
responsible for this very common, yet complex pheno-
type. Although a half-dozen loci have been reported after
analysis of conventional genomewide scans of “high-risk
families,” confirmation studies have been few, and, until
recently, there have been no public reports of cloned loci.
As investigators in the field have wrestled with issues
related to the variability in disease phenotype, large
numbers of sporadics in the population, and statistical
issues related to age-dependent penetrance, it seemed
that the prostate cancer field was beginning to follow
the tortuous path set by investigators mapping genes for
diabetes and schizophrenia. Last month, those issues
were temporarily set aside, when Rebbeck et al. (2000),
in a clinic-based, follow-up study to the reported cloning
of HPC2/ELAC2 (Tavtigian et al. 2000), demonstrated
that men who carry both of two common polymor-
phisms in the HPC2/ELAC2 gene experience a modest
increase in risk for prostate cancer. HPC2/ELAC2 seems
well established, therefore, as the first prostate can-
cer–susceptibility gene characterized by positional clon-
ing (Tavtigian et al. 2000). These data, together with
several genome-scan reports and a host of follow-up
papers, offer intriguing lessons for those in the field,
suggesting new ways to approach the difficult problem
of understanding prostate cancer susceptibility.
Inherited Prostate Cancer
The familial aggregation of prostate cancer was first re-
corded by Morganti et al. (1956), who noted that pa-
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tients with prostate cancer reported a higher frequency
of the disease among relatives than did hospitalized con-
trols. Subsequently, Woolf (1960) found that deaths due
to prostate cancer were three times as high among the
fathers and brothers of men dying from prostate cancer
than among deceased relatives of men dying from other
causes. The notion that there are prostate cancer–
susceptibility genes has since been suggested by case-
control, cohort, and twin studies (Steinberg et al. 1990;
Gro¨nberg et al. 1994, 1996; Whittemore et al. 1995b;
Page et al. 1997; Lichtenstein et al. 2000). The effect is
strongest among first-degree relatives, where the relative
risk estimates are in the range of 1.7–3.7 (Fincham et al.
1990; Steinberg et al. 1990; Hayes et al. 1995; Whitte-
more et al. 1995b). Several of these studies found no
significant increase in risk for men reporting second-
degree affected relatives (Steinberg et al. 1990; Spitz et
al. 1991; Whittemore et al. 1995b). However, younger
ages at diagnosis and multiple relatives with prostate
cancer were both associated with even higher relative
risks. For example, compared with men having no family
history of prostate cancer, men with three or more first-
degree relatives with prostate cancer have an almost 11-
fold increased risk of the disease (Steinberg et al. 1990).
Although most studies focused on whites, similar two-
fold or higher elevations in risk associated with a family
history of prostate cancer have been reported for Asians
(Whittemore et al. 1995b) and for blacks in the U.S.
(Hayes et al. 1995; Whittemore et al. 1995b) and in
Jamaica (Glover et al. 1998). Although most of the data
seem to point toward autosomal dominant genes, evi-
dence for an X-linked or recessive mode of inheritance
has also been reported, on the basis of observation of a
higher relative risk for prostate cancer among men who
report an affected brother(s) with prostate cancer than
among those reporting an affected father (Monroe et al.
1995; Narod et al. 1995).
The first segregation analysis, completed by Carter et
al. (1992), provided insight into the likely features of
HPC genes. They examined 691 families affected by
prostate cancer ascertained through 740 consecutive
probands undergoing radical prostatectomy for primary
clinically localized prostate cancer at Johns Hopkins
during 1982–1989. The results suggested that familial
clustering of disease among those with early onset was
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best explained by the presence of rare autosomal dom-
inant, highly penetrant allele(s) ( ), with car-qp .0030
riers having an 88% cumulative risk of disease by age
85 years, compared with only 5% for noncarriers (Car-
ter et al. 1992). HPC gene(s) were predicted to account
for ∼43% of early-onset disease (at age 55 years) and
9% of total prostate cancer in men diagnosed through
age 85 years.
In two other segregation analyses, similar conclusions
were reached. The results of the study by Gro¨nberg et
al. (1997a), from a population-based sample of 2,857
Swedish nuclear families, also support an autosomal
dominant mode of inheritance but suggest a higher fre-
quency of the susceptibility allele (1.67%) and a lower
lifetime penetrance (63%). Schaid et al. (1998), who
analyzed 4,288 men undergoing radical prostatectomy
for clinically localized disease at the Mayo Clinic, re-
ported that no single-gene model of inheritance clearly
explained the observed familial clustering. But the best-
fitting model was also that of a rare autosomal domi-
nant susceptibility gene, with the best fit observed in
probands diagnosed at !60 years of age. These inves-
tigators proposed a gene population frequency of .006,
with a risk of 89% by age 85 years, for carriers. In
addition, their data suggest that a high proportion of
prostate cancer is accounted for by autosomal dominant
genes, ∼68% at age !60 years (Schaid et al. 1998).
These conclusions are supported by other types of stud-
ies. For instance, in an analysis of 44,788 pairs of twins
from the Swedish, Danish, and Finnish twin registries,
Lichtenstein et al. (2000) concluded that 42% (95%
confidence interval (CI), 29%–50%) of prostate cancer
risk may be accounted for by heritable factors.
A generally agreed upon definition of hereditary or
high-risk prostate cancer families now exists. Referred
to as the “Hopkins Criteria,” hereditary families are
those in which there is either (1) prostate cancer in three
or more first-degree relatives; (2) prostate cancer in three
successive generations of either the maternal or paternal
lineages; or (3) a cluster of two relatives affected at age
55 years (Carter et al. 1993). Armed with these cri-
teria, we and others have collected large data sets of
likely hereditary families and have undertaken ge-
nomewide scans expecting, perhaps naively, that, in this
genomic era, the mapping and cloning of prostate can-
cer–susceptibility genes could be accomplished rapidly.
On the basis of experience gathered to date, this has
proven to be anything but the case.
Mapping HPC Genes
The first prostate cancer locus, HPC1, was mapped to
chromosome 1 in 1996 by a team of investigators from
the Johns Hopkins Medical Center, the National Human
Genome Research Institute, and Umea˚ University in
Sweden. The study, which generated enormous excite-
ment in the field, used 91 high-risk prostate cancer fam-
ilies from the U.S. and Sweden (Smith et al. 1996) and
demonstrated strong evidence of linkage at 1q24-25. A
maximum multipoint LOD score of 5.43 was obtained
under the assumption of heterogeneity, with 34% of
families hypothesized to be linked. These conclusions
were supported by nonparametric multipoint linkage
(NPL) analysis, using the program GENEHUNTER
(Kruglyak et al. 1996), with highly significant nonpar-
ametric multipoint Z scores reported (maximum 4.71,
). The NPL statistic is considered most ap-P ! .000001
propriate for analysis of complex traits such as prostate
cancer because it is not based on assumed genetic mod-
els; rather, it simply compares the observed versus the
expected sharing of chromosomal regions identical by
descent among affected relatives (Ott 1996). The initial
report did not suggest that any subgroup of families was
more or less likely to be linked, although a strong age-
at-onset effect has since been noted in both North Amer-
ican and Swedish families, with nearly all putatively
linked families having an average age at diagnosis of
!65 years (Gro¨nberg et al. 1997c, 1999).
Given the strength of the initial result, it was sur-
prising that subsequent reports attempting to confirm
linkage were inconclusive. The most confirmatory re-
sults came from nonparametric multipoint analyses
published independently by groups at the University of
Michigan and at Stanford University. Cooney et al.
(1997) and Hsieh et al. (1997) observed maximum NPL
Z scores of 1.58 and 1.71, respectively, and P values of
.057 and .046, in their complete data sets of 59 and 92
families. Results were slightly stronger in families di-
agnosed earlier in life (at age !67 years) or that best fit
the definition of HPC. Although these data are certainly
indicative of linkage, it was surprising that the results
did not reach a P value of .01, which was needed for
formal replication of linkage (Lander and Kruglyak
1995). In addition, several papers, including two from
our own group, were published that used seemingly
similar data sets to those described by Smith et al.
(1996) but nevertheless found no evidence for HPC1
linkage (McIndoe et al. 1997; Berthon et al. 1998; Eeles
et al. 1998; Goode et al. 2000). Given the strength of
the original result, these reports were surprising and
provided the first hints that the mapping and subsequent
cloning of prostate cancer genes might prove more com-
plex than originally suspected. This has, indeed, proven
to be the case.
Mapping of loci to chromosomes 1q42.2-43, Xq27-
28, 1p36, and, very recently, to 20q13 followed quickly,
as did an additional series of reports that were unable
to provide statistically significant confirmation of link-
age (Whittemore et al. 1999; Berry et al. 2000; Peters
et al., in press). For instance, linkage to Xq27-28 was
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reported by a consortium of four groups after they
combined independently collected data sets from Johns
Hopkins Medical Institutions, Tampere University Hos-
pital in Finland, Umea˚ University in Sweden, and the
Mayo Clinic. The results were strongly significant, with
a maximum two-point LOD score of 4.6 (recombina-
tion fraction [v] 0.26), and both parametric and non-
parametric multipoint analyses were consistent. Linkage
to Xq27-28 was predicted to account for 16% of pros-
tate cancer in the data set of 360 families. Yet, again,
there has been difficulty in confirming these seemingly
incontrovertible findings in independent data sets, with
!5% of families projected to be linked in other pub-
lished reports (Peters et al., in press).
Statistical Power Considerations
What possible explanations can account for these dis-
parate results? Overall, the difficulties seem to stem from
genetic heterogeneity inherent in prostate cancer and
from the accompanying difficulty of developing appro-
priate transmission models. The solutions may lie in
“model-free” methods of analysis and in stratification
of data into homogeneous subsets for subsequent anal-
ysis. The key piece of supporting data was provided in
an analysis of HPC1 (Neuhausen et al. 1999). In an
analysis of 41 large Utah families, with a mean number
of affected men per family of 10.7, Neuhausen et al.
confirmed linkage by reporting two- and three-point
LOD scores of 1.73 ( ) and 2.06 ( ),Pp .005 Pp .002
respectively, at 1q24-25. The authors hypothesize that
the extraordinarily large number of cases per family pro-
vided sufficient power to overcome the problem of spo-
radic cases in families segregating disease mutations.
They argued that this would be critical for untangling
the genetics of prostate cancer overall. The authors also
observed that adjusting the transmission model to better
fit the true age at onset observed in the Utah families
strengthened the results. This latter fact suggested that
model misspecification could easily be a factor contrib-
uting to the contradictory results, and that nonpara-
metric or non–model-driven analyses are the most useful
approach, as had been suggested by Cooney et al. (1997)
and by Hsieh et al. (1997), in their initial confirmatory
reports of HPC1.
Suspecting that the real problem might indeed be one
of power, the International Consortium for Prostate
Cancer Genetics (ICPCG) agreed to a single, very large,
joint analysis, thus providing the second piece of the
puzzle (Xu and ICPCG 2000a). Researchers from North
America, Australia, Finland, Norway, Sweden, and the
United Kingdom pooled their data and analyzed a set
of 772 families for linkage to 1q24-25. The initial anal-
ysis provided only weak evidence for linkage at 1q24,
with a peak parametric multipoint LOD score, assuming
heterogeneity (HLOD), of 1.40 ( ), and the es-Pp .01
timated proportion of linked families was only 6%. The
extraordinary size of the data set, however, meant that
stratifications to develop homogeneous subsets could be
undertaken with confidence. These analyses confirmed
linkage in a subset of families and revealed that, overall,
a disproportionate amount of linkage was derived from
families characterized by male-to-male inheritance pat-
terns. Within such families, the strongest evidence was
contributed by those with an early mean age at diag-
nosis (!65 years) or by those who had strong family
histories of disease (five or more affected men). Data
from nonparametric analysis supported these findings,
as well (Xu and ICPCG 2000b). These conclusions are
also supported in a report by Berry et al. (2000), who
also showed modest evidence for linkage to HPC1 when
the analysis was restricted to a data set of 102 families
with clear evidence of male-to-male transmission (NPL
p 1.99, ).Pp .03
Overall, these results suggest three guiding principles.
First, the number of genes that contribute to prostate
cancer susceptibility is sufficiently large for initial re-
ports of linkage to reflect, in part, the draw of a “lucky
hand,” where a significant number of families may at-
tribute their disease to a specific locus. If all published
reports of linkage are to be believed, there are at least
six HPC loci and probably more. As a result, power
will always be limited in confirmatory studies that will
be done on data sets unlikely to represent such a “lucky
hand.” If the number of genes is large, as it appears to
be for prostate cancer, the more representative a limited-
sized data set of families is of the real distribution of
prostate cancer loci in the general population, the less
likely that data set will be to confirm any single finding
of linkage or to generate any reports of linkage to new
loci.
Second, model misspecification is a serious problem
when diseases that are genetically heterogeneous are
mapped. Segregation analyses produce summary data
but cannot specify the allele frequency or penetrance of
any single locus. In the case of the data presented by
Neuhausen (1999), the model-misspecification hypoth-
esis is supported by the fact that LOD scores using the
Utah-specific model generally maximized at values of v
closer to 0 than what was observed when using the
model presented by Smith et al. (1996). The Utah model
includes a higher sporadic disease rate than the model
presented by Smith et al.—in particular, for cases di-
agnosed at older ages. Although this causes some loss
of power, it provides more accurate data. The so-called
model-free analysis may provide the best approach.
Finally, development of homogeneous subsets for
both finding and confirming linkage is an effective strat-
egy. The mapping of the HPCX and CAPB loci provides
two examples. The initial mapping of HPCX to Xq27-
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28 relied on families without evidence of male-to-male
transmission. These families accounted for about two-
thirds of the final significant LOD score. Given a lack
of observed linkage in black families to Xq27-28, strat-
ification by race further strengthened the results (Lange
et al. 1999).
The mapping of the CAPB locus also illustrates the
power of subset identification. Focusing only on pros-
tate cancer families with a confirmed family history of
primary brain cancer, a prostate cancer–susceptibility
locus at 1p36 was detected (Gibbs et al. 1999). This
region was of particular interest, since an excess of brain
and CNS cancers had been reported in high-risk pros-
tate cancer families (Goldgar et al. 1994; Isaacs et al.
1995) and because 1p36 is a region of frequent loss of
heterozygosity in brain tumors (Bello et al. 1995a,
1995b; Kraus et al. 1995; White et al. 1995). The max-
imum two-point LOD score in these 12 families was
3.22 at v p 0.06, with most of the result coming from
families with a mean age of !66 years at diagnosis of
prostate cancer (maximum two-point LOD score of
3.65 at v p 0.0). The NPL score across the most nar-
rowly defined region of interest, however, was not suf-
ficiently robust to declare a significant finding of linkage
(2.24, ). This may reflect the fact that GENE-Pp .02
HUNTER uses only data from affected individuals.
Thus, older unaffected men who did not share the af-
fected haplotype and contributed significantly to the
parametric LOD score results do not contribute to the
NPL result. The CAPB locus is estimated to be only a
small player in prostate cancer susceptibility overall,
perhaps not 15%. However, it illustrates nicely how
development of homogeneous subsets can greatly en-
hance power.
One additional strategy for developing homogeneous
subsets is by consideration of clinical features of disease.
But given that any single family will likely have men
presenting with widely different stages of disease and
tumor grades at diagnosis, it is not obvious how these
issues are best handled statistically. There is no clear
way to “average” stage and grade across a family and
it is not obvious that it is appropriate, since there is no
indication that stage or tumor grade is a good indicator
of hereditary disease. One way around this problem is
to consider only a subset of disease types, such as ad-
vanced stage or high grade.
Clinical Features of Disease
Witte et al. (2000) have used clinical features of disease
to try to map genes responsible for high-grade disease,
specifically, by stratifying families on the basis of the
Gleason score. Because most prostate tumors express
more than one histologic glandular pattern, the Gleason
system records a grade with a range of 1–5 for the two
predominant patterns for a given tumor (e.g., 4 and 5).
These two numbers are added, to give a Gleason score
in the range of 2–10 (i.e., 9 in the example). Tumors
with low Gleason scores tend to be small in volume and
have low metastatic potential, whereas tumors with high
Gleason scores tend to be larger in volume and have
significant metastatic potential. The preoperative Glea-
son score correlates closely with important indicators of
extent of disease, such as pelvic lymph node involvement
and distant metastasis (Gleason 1977). Witte et al.
(2000), using the Gleason score taken from biopsy or
prostatectomy as a quantitative measure of disease ag-
gressiveness, conducted a genomewide linkage analysis
of 326 affected sib pairs, reflecting 233 unique families.
Their scan highlighted regions on chromosome 5q31-
33, 7q32, and 19q12, as containing potential loci im-
portant in the development of aggressive disease (P p
.0002, .0007, and .0004, respectively). None of these
loci was strongly suggested in an independent sibpair
analysis of the same samples stratified by family history
considerations, age at diagnosis, and family history of
breast cancer (Suarez et al. 2000a).
Genomewide Scans for Prostate Cancer
Given the apparent value of stratifying data sets by fea-
tures such as age at onset, family history of other cancers,
or clinical characteristics, some thought should be given
to what results are likely to stand the test of time. Thus
far, three complete genome scans for prostate can-
cer–susceptibility genes have been published. In the scan
of Smith et al. (1996), the strongest evidence for linkage
was at HPC1, although two-point analysis also revealed
a LOD score of 1.5 at D4S430 and LOD scores of
1.0 at several loci including markers at Xq27-28. A
second scan, from our own group (Gibbs et al. 2000),
reported two-point LOD scores of 1.5 for chromo-
somes 10q, 12q, and 14q, when the entire data set is
considered under an autosomal dominant model of in-
heritance and for chromosomes 1q, 8q, 10q, and 16p,
when a recessive model of inheritance is considered. The
strongest data for all 94 families were observed at
D10S1223 (LOD 2.46, vp 0.04) and at D8S2324 (LOD
2.17, vp .10), under the recessive model. Stratification
by age at diagnosis revealed several other regions of
interest, including two-point LOD scores of 2.35, also
at D10S1223, for 50 families with a mean age at di-
agnosis of !66 years, and of 3.02, at ATA34E08 on
chromosome 11, for 44 families with a mean age at
diagnosis of 66 years, both analyzed under an auto-
somal dominant model. None of these results meet the
statistical criteria for significance, but they are clearly
worth following up in larger data sets. What is less clear,
however, is how to balance the statistical penalty for
multiple sampling schemes with the desire to develop
homogeneous subsets to reduce locus heterogeneity.
The scan published by Suarez et al. (2000a) faces
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similar issues. In their initial scan, these authors ana-
lyzed 504 brothers from 230 multiplex sibships and
identified five regions with nominal evidence for linkage
on 2q, 12p, 15q, 16q, and 16p. Three preplanned sub-
analyses were performed, stratifying families by means
of the “Hopkins Criteria” of likely “hereditary” versus
“nonhereditary,” by age at onset, and by a family his-
tory of breast cancer. Several additional loci were iden-
tified in these specific subsets, with the strongest signals
on chromosomes 1p35.1, 4q, and 1q, in a region prox-
imal to the HPC1 locus, and on 21q. When the data
were examined in totality, the most consistent evidence
for linkage, overall, in several partitions, was on chro-
mosome 16 (Suarez et al. 2000a, 2000b).
HPC2/ELAC2
Given the strength of the linkages observed, particularly
at 1q24-25 and at Xq27-28, and the expertise of the
groups involved, it was generally expected that these
would be the first prostate cancer genes cloned. Instead,
as we learned in last month’s issue of the American Jour-
nal of Human Genetics, and as mentioned above, the
HPC2/ELAC2 gene, located on chromosome 17p, claims
that distinction (Tavtigian et al. 2000). HPC2/ELAC2
was mapped by taking advantage of the Utah Family
Resource, a set of extended pedigrees, each with several
affected individuals, that has proven invaluable for map-
ping and cloning cancer genes in the past (Cannon et al.
1982; Miki et al. 1994; Wooster et al. 1994). HPC2/
ELAC2 was originally mapped in a set of 33 pedigrees
with a maximum two-point LOD score of 4.5 (vp .07).
To clone the gene, the data set was expanded to 127
families, which, overall, failed to provide a significant
LOD score. After excluding branches of the family po-
tentially linked to HPC1, and by focusing on a subset
of families who either had individual family LOD scores
of 1.0 or who had six or more cases that shared a
haplotype, irrespective of LOD score, the authors
quickly zeroed in on a likely candidate. Mutational anal-
ysis revealed a subset of carriers in one family with a
germline insertion that leads to premature termination
of translation after incorporation of 67 miscoded resi-
dues. A common missense variant, which changed a ser-
ine to a leucine at amino acid 217, was also found. This
gene was named “HPC2/ELAC2,” since it is the larger
of two human genes that were found to be homologues
of Escherichia coli elaC.
Examination of 45 additional unrelated cases diag-
nosed at age 55 years failed to reveal any additional
frameshift mutations, suggesting that truncation of the
protein, caused by germline changes, is unlikely to be
a common cause of prostate cancer among high-risk
families. It did, however, reveal a relatively rare Ala to
Thr change at amino acid 541. The latter was only
observed in the presence of the Ser217Leu variant and
seemed to segregate with disease in at least one family
(Tavtigian et al. 2000). In a clinic-based study of 359
incident–prostate cancer cases and 266 male controls
matched for age and race, Rebbeck et al. (2000) ob-
served that the relative risk of having prostate cancer
is increased in men who carry the Leu217/Thr541 var-
iants (OR 2.37; 95% CI 1.06–5.29). The Thr541 mis-
sense is present in 2.9% of unaffected controls and the
Leu217, in 31.6%. The estimated risks did not differ
significantly by family history or race. If the carrier fre-
quency of the Leu217/Thr541 genotype is assumed to
be ∼4%, and the relative risk associated with the at-
risk genotype is 2.4, then the percent of prostate cancer
in the population caused by this genotype is ∼5.3%.
The functional significance of these missense changes is
not known, although the Thr541 change is adjacent to
a highly conserved histidine motif, suggesting that it lies
near a functionally relevant region of the protein. Pop-
ulation-based case-control studies are needed to deter-
mine the contribution of this locus to prostate cancer
in the general population.
The Leu217/Thr541 change in the HPC2/ELAC2
gene does not represent the first missense change to be
associated with prostate cancer susceptibility. Analyses
of genes important in steroid metabolism and signaling
have identified several others. For instance, several stud-
ies show an association between shorter (CAG)n repeats
within exon one of the androgen-receptor gene and
prostate cancer risk (Giovannucci et al. 1997; Stanford
et al. 1997). Also, missense changes within the steroid
5-alpha-reductase type II gene, which are believed to
increase the catalytic activity of the enzyme, are asso-
ciated with an increased risk of advanced prostate can-
cer (Reichardt et al. 1995; Makridakis et al. 1999; Jaffe
et al. 2000). Polymorphisms in several positions in the
vitamin D receptor gene are also associated with an
increased risk of disease (Taylor et al. 1996; Ingles et
al. 1997). What is unique about the reports of Tavtigian
and Rebbeck is that this is the first announced prostate
cancer–susceptibility gene cloned after a genomewide
scan of high-risk families, and the first for which there
is evidence that both frameshift changes and missense
changes are disease associated. These studies hopefully
pave the way for additional, similar reports at other
loci.
Lessons Learned
It seems, therefore, that mapping and cloning of prostate
cancer genes will be complicated by three issues. First,
there are a large number of men with sporadic disease
in the population. An estimated one in eight men will
get prostate cancer at some point in their lives (Ries et
al. 1999), with ∼180,400 men diagnosed in the year
2000 (Greenlee et al. 2000). Indeed, in the year 2000,
prostate cancer accounted for 29% of all newly diag-
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nosed cancers (Greenlee et al. 2000). Certainly, a portion
of these men will not carry germline mutations, but will
be related to individuals who do. A priori, there seem
to be no discernible differences in morbidity or mortality
in genetic versus nongenetic cases, with the exception
that hereditary cases tend to be diagnosed earlier in life.
A caveat to this stems from a report by Gro¨nberg et al.
(1997b), who argue that high-grade cancers and ad-
vanced-stage disease were more common in families
whose disease is potentially linked to HPC1. This has,
however, been debated by others (Laniado 1998;
Walther 1998). Narrowing a putative region of linkage
can be very difficult; a single recombinant whose disease
is not due to a germline change can incorrectly be used
to define the critical region, thus misleading investigators
to focus their search for candidate genes in the wrong
region of the chromosome.
A second major consideration relates to age at onset,
which, in distinguishing individuals with inherited ver-
sus sporadic disease, has proven to be less hopeful than
hoped for. In the United States, the average age at di-
agnosis for prostate cancer is 71 years for whites and
69 years for blacks (Stanford et al. 1999). Early age at
diagnosis is generally defined as 60 years, with men
in this age group accounting for !10% of all prostate
cancers (Stanford et al. 1999). However, most of the
data sets collected for mapping report a mean age at
diagnosis of ∼65 years, and the identification of men
diagnosed at age !50 years is very rare (Xu and ICPCG
2000a). By contrast, the median age at diagnosis for
breast cancer is 63 years (Ries et al. 2000), and in fam-
ilies segregating BRCA1 and BRCA2 mutations, it is
not uncommon to observe women diagnosed in their
twenties. Thus, for breast cancer, the distinction be-
tween those diagnosed with early-onset disease and
those diagnosed at the mean age is greater than that
observed for prostate cancer. Therefore, the use of age
at diagnosis to estimate the likelihood that an individ-
ual’s disease is inherited is probably less accurate for
prostate than for breast cancer.
Finally, there is enormous variation in the phenotype
of disease at diagnosis as well as disease progression
within single families. The introduction of prostate-spe-
cific antigen (PSA) testing in the mid to late 1980s has
probably contributed to that variability. On the basis
of statistical modeling, Etzioni et al. (1998) estimate
that 50% of new cases are unlikely to have come to
clinical diagnosis in the absence of PSA testing. In ad-
dition, men diagnosed by PSA, as opposed to digital
rectal examination or physical symptoms, are diagnosed
∼3–5.5 years earlier (Gann et al. 1995; Whittemore et
al. 1995a; Pearson et al. 1996). Stratification by year
at diagnosis has recently been proposed as a useful way
to develop homogeneous subsets for linkage studies.
Support for this proposal was recently provided by Xu
et al. (2000), who reported that disease in men diag-
nosed !1990—i.e., before PSA came into common use
in the U.S.—is more likely to be linked to HPC1 than
disease in men diagnosed 11990, suggesting that a time-
dependent phenocopy rate may be contributing to ap-
parent disease heterogeneity.
Given all the above, how best are we to proceed as
a field if we wish to most efficiently clone the major
prostate cancer–susceptibility genes? Clearly, we now
recognize that HPC is in some ways more complicated
and certainly involves more loci than do other common
cancers, such as breast. Statistical power is almost al-
ways limiting in such situations, and combined analysis
will be key for understanding the true contribution of
any locus to disease in the overall population, as will
be careful consideration of the statistical model. The
stratification of data sets by clinical features and other
cancers has only barely been tapped as a mechanism for
defining homogeneous subsets for analysis. But we need
to be wary of the statistical penalty that must be paid
for such an approach. Finally, missense changes may be
one of the important ways in which prostate can-
cer–susceptibility genes affect disease. Therefore, we
need to become more facile in moving between data sets
of high-risk families and population-based case-control
studies. One suspects that if we can adequately define
ways in which to tackle the genetics of prostate cancer,
we may, in the end, develop a clear blueprint for how
to tackle the genetics of other complex diseases.
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